메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

논문 기본 정보

자료유형
학술저널
저자정보
Se Jin Oh (Korea University College of Medicine) Jaeyoon Lee (Northeastern University) Yukang Kim (Korea University College of Medicine) Kwon-Ho Song (Korea University College of Medicine) Eunho Cho (Korea University College of Medicine) Minsung Kim (Korea University College of Medicine) Heejae Jung (Korea University College of Medicine) Tae Woo Kim (Korea University College of Medicine)
저널정보
대한면역학회 Immune Network Immune Network Vol.20 No.1
발행연도
2020.2
수록면
94 - 104 (11page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
Cancer immunotherapy, in the form of vaccination, adoptive cellular transfer, or immune checkpoint inhibitors, has emerged as a promising practice within the field of oncology. However, despite the developing field"s potential to revolutionize cancer treatment, the presence of immunotherapeutic-resistant tumor cells in many patients present a challenge and limitation to these immunotherapies. These cells not only indicate immunotherapeutic resistance, but also show multi-modal resistance to conventional therapies, abnormal metabolism, stemness, and metastasis. How can immunotherapeutic-resistant tumor cells render multi-malignant phenotypes? We reasoned that the immune-refractory phenotype could be associated with multi-malignant phenotypes and that these phenotypes are linked together by a factor that acts as the master regulator. In this review, we discussed the role of the embryonic transcription factor NANOG as a crucial master regulator we named “common factor” in multi-malignant phenotypes and presented strategies to overcome multi-malignancy in immunotherapeutic-resistant cancer by restraining the NANOGmediated multi-malignant signaling axis. Strategies that blunt the NANOG axis could improve the clinical management of therapy-refractory cancer.

목차

ABSTRACT
INTRODUCTION
THE CAUSE OF MULTI-MALIGNANCY PRESENTED IN IMMUNOTHERAPEUTIC-ESISTANT TUMOR CELLS : CANCER IMMUNOEDITING
MULTI-MALIGNANT PHENOTYPES : THE COMMON FEATURES BETWEEN IMMUNOTHERAPEUTIC-RESISTANT AND STEM-LIKE TUMOR CELLS
IDENTIFICATION OF THE MULTI-MALIGNANT “COMMON FACTOR” : NANOG
UNDERSTANDING OF THE NANOG-MEDIATED SIGNALING PATHWAY IN MULTI-MALIGNANT PHENOTYPES
THERAPEUTIC OPPORTUNITIES THROUGH ACTIONABLE DRUGS TARGETING THE NANOG SIGNALING AXIS
CONCLUSION
REFERENCES

참고문헌 (55)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0